Immuron Ltd Engages Pullan Consulting for IMM-529 Partnering Strategy [VIDEO]
Immuron has engaged specialist firm Pullan Consulting to secure a strategic partner for IMM-529, its Phase 2-ready CDI therapy backed by an FDA-cleared IND and a projected US$400M base case revenue opportunity.
Key Takeaways
- Immuron has appointed Pullan Consulting — a firm with a 20-year track record of executing five to twelve partnering transactions annually — to secure a strategic partner for IMM-529, its CDI therapy.
- An independent opportunity assessment by Lumanity projects base case yearly revenue for IMM-529 at US$400M, with up to ~98,000 patients eligible at first recurrence positioning.
- IMM-529 holds an FDA-cleared IND (IND 32095) and has completed all key trial-readiness milestones, including site selection, protocol finalisation, and drug product manufacture, making it immediately actionable for a partner.
- Pre-clinical data showed IMM-529 prevented primary CDI in 80% of cases and protected against recurrence in 67% of cases, both at statistically significant p-values, with cross-reactivity confirmed across multiple human C. diff strains including hypervirulent ones.
- Historical CDI licensing deals provide a wide benchmark range — upfront payments of US$1M–$50M and milestones up to US$570M — with Immuron describing a successful partnership as potentially transformational for the company.
![Algorae Pharmaceuticals Ltd AI Platform Validated With 2.5x Synergy Lift [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2Fb9b14ab6-a11f-47ad-85bf-491be1bf9b582Fimage_0.jpg)
![Genetic Signatures Ltd Gets BCAL Backing Through 10.2% Stake Purchase [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2Fb377bf6c-56e4-43e5-9dd1-8e08cd86e8c82Fimage_0.jpg)
![Algorae Pharmaceuticals Ltd Clarifies NSW Health Supply Panel Terms [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2Fbad3a004-c24a-4185-95c9-6312cede3da92Fimage_0.jpg)
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time
About the Publisher
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
Disclosure
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.